Abbott turned a page for its US powder infant formula business in its latest quarter and forecast more progress ahead after meeting its federal Women, Infants, and Children program order backlog and starting distribution to retailers.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?